05/05/2026
Major Milestone in Regenerative Medicine Research
Cord for Life® has completed enrollment and dosing for its FDA-authorized Phase 1 clinical trial evaluating an investigational umbilical cord blood-derived biological therapeutic for lower back pain associated with Sacroiliac Joint Syndrome.
Preliminary Phase 1a observations include a favorable early safety profile, no unexpected adverse events reported to date, symptom severity reduction among all nine participants within 3–6 months, and positive quality-of-life trends.
Subject to regulatory review, Cord for Life® anticipates initiating Phase 2 later this year to further evaluate dosing and expanded enrollment.